Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Kanamycin Sulfate

FDA-approved product (capsule, oral), marketed as Kanamycin, Kanamycin Sulfate, Kantrex and 1 more.

Registered studies
50+
Lab records
73
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Kanamycin Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Eye infection

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Antibiotics; Other aminoglycosides
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01GB04; WHO ATC A07AA08; WHO ATC S01AA24

Repurposing investigation

Kanamycin Sulfate is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA6.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli4.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae63.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis78.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 1 of 11 lab records
  • E. coli: measured active in 9 of 24 lab records
  • K. pneumoniae: measured active in 4 of 11 lab records
  • M. tuberculosis: measured active in 26 of 27 lab records
Open Kanamycin Sulfate in ChEMBL Registered studies below
Show the 73 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Kanamycin Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluation of Short Antibiotic Combination Courses Followed by Aerosols in Cystic Fibrosis

    NCT03066453 · start 2017-06-13

    Registered record
    Registry ID
    NCT03066453
    Conditions
    Cystic Fibrosis
    Interventions
    Tobi Inhalant Product; Nebcin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2017-06-13
    Completion
    2020-01-16
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionTobi Inhalant Product; Nebcin
    PhasePhase 3
    Registry statusTerminated

  • Selective Decontamination of the Digestive Tract in Intensive Care Unit Patients

    NCT02389036 · start 2017-05-01

    Registered record
    Registry ID
    NCT02389036
    Conditions
    Critical Illness; Sepsis; Septic Shock; Ventilator Associated Pneumonia
    Interventions
    SDD Oral Paste; SDD Gastric Suspension; Intravenous Antibiotic
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-05-01
    Completion
    2023-04-26
    Enrolment
    20,010

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCritical Illness; Sepsis; Septic Shock; Ventilator Associated Pneumonia
    InterventionSDD Oral Paste; SDD Gastric Suspension; Intravenous Antibiotic
    PhasePhase 3
    Registry statusCompleted

  • Tobramycin Delivered by Nebulized Sonic Aerosol for Chronic Rhinosinusitis Treatment of Cystic Fibrosis Patients

    NCT02888730 · start 2017-02-16

    Registered record
    Registry ID
    NCT02888730
    Conditions
    Cystic Fibrosis; Rhinosinusitis; Lung Diseases
    Interventions
    Tobramycin nebulized nasally; Physiologic serum nebulized nasally
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2017-02-16
    Completion
    2019-07-08
    Enrolment
    86

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis; Rhinosinusitis; Lung Diseases
    InterventionTobramycin nebulized nasally; Physiologic serum nebulized nasally
    PhasePhase 3
    Registry statusTerminated

  • IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy

    NCT02918409 · start 2016-08-26

    Registered record
    Registry ID
    NCT02918409
    Conditions
    Cystic Fibrosis
    Interventions
    Colistin; Tobramycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-08-26
    Completion
    2021-11-22
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionColistin; Tobramycin
    PhasePhase 4
    Registry statusCompleted

  • Effects of Holy-Comod and Tears Naturale Forte in Patients After Phaco+IOL

    NCT02817191 · start 2016-06

    Registered record
    Registry ID
    NCT02817191
    Conditions
    Age-related Cataract
    Interventions
    Hylo-Comod eye drop; Tears Naturale Forte eye drop
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2016-06
    Completion
    2016-11
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAge-related Cataract
    InterventionHylo-Comod eye drop; Tears Naturale Forte eye drop
    PhaseNot applicable
    Registry statusUnknown

  • An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis

    NCT02454205 · start 2015-11-12

    Registered record
    Registry ID
    NCT02454205
    Conditions
    Tuberculosis; Multidrug Resistant Tuberculosis; Extensively-drug Resistant Tuberculosis
    Interventions
    Linezolid; Bedaquiline; Levofloxacin; Pyrazinamide; Isoniazid; Ethionamide; Terizidone; Moxifloxacin; Kanamycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2015-11-12
    Completion
    2021-08-30
    Enrolment
    154

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Multidrug Resistant Tuberculosis; Extensively-drug Resistant Tuberculosis
    InterventionLinezolid; Bedaquiline; Levofloxacin; Pyrazinamide +5 more
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Once Daily Aminoglycoside Pharmacokinetics and Optimal Dosing in the Burn Population: A Prospective Study

    NCT02269969 · start 2015-03

    Registered record
    Registry ID
    NCT02269969
    Conditions
    Burns; Infection
    Interventions
    Tobramycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2015-03
    Completion
    2015-12
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBurns; Infection
    InterventionTobramycin
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Impact of 30 mg/kg Amikacin and 8 mg/kg Gentamicin on Serum Concentrations in Critically Ill Patients With Severe Sepsis

    NCT02898961 · start 2014-10

    Registered record
    Registry ID
    NCT02898961
    Conditions
    Sepsis
    Interventions
    30 mg/kg amikacin or 8 mg/kg gentamicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-10
    Completion
    2016-12-31
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis
    Intervention30 mg/kg amikacin or 8 mg/kg gentamicin
    PhasePhase 4
    Registry statusCompleted

  • Pharmacokinetic and Pharmacoscintigraphic Comparison of TobrAir® 6.0 With TOBI® and TOBI® Podhaler™

    NCT02207426 · start 2014-07

    Registered record
    Registry ID
    NCT02207426
    Conditions
    Healthy
    Interventions
    Tobramycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-07
    Completion
    2014-09
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTobramycin
    PhasePhase 1
    Registry statusCompleted

  • Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis

    NCT02081963 · start 2014-03

    Registered record
    Registry ID
    NCT02081963
    Conditions
    Non-Cystic Fibrosis Bronchiectasis
    Interventions
    Amikacin; Normal saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-03
    Completion
    2016-12
    Enrolment
    178

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Cystic Fibrosis Bronchiectasis
    InterventionAmikacin; Normal saline
    PhasePhase 4
    Registry statusCompleted

  • Which Apparatus for Inhaled Pentamidine?

    NCT02277808 · start 2013-12

    Registered record
    Registry ID
    NCT02277808
    Conditions
    Healthy
    Interventions
    500mg Amikacine (Amukin®) diluted in 4mL NaCl (0,9%); Respirgard II; Isoneb®
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Unknown
    Start
    2013-12
    Completion
    Not recorded
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Intervention500mg Amikacine (Amukin®) diluted in 4mL NaCl (0,9%); Respirgard II; Isoneb®
    PhaseEarly phase 1
    Registry statusUnknown

  • Clinical Trial to Investigate the Pharmacokinetics of Second-Line Anti-Tuberculosis Agents

    NCT02128308 · start 2013-11

    Registered record
    Registry ID
    NCT02128308
    Conditions
    Healthy
    Interventions
    Levofloxacin and Streptomycin added; Moxifloxacin and Kanamycin added
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-11
    Completion
    2014-01
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionLevofloxacin and Streptomycin added; Moxifloxacin and Kanamycin added
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin by a Novel Device in Patients With Non Cystic Fibrosis Bronchiectasis

    NCT02035488 · start 2013-10

    Registered record
    Registry ID
    NCT02035488
    Conditions
    Bronchiectasis
    Interventions
    Tobramycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2013-10
    Completion
    2014-12
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBronchiectasis
    InterventionTobramycin
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Bioequivalence and Safety of Vantobra and TOBI in Healthy Subjects

    NCT01953367 · start 2013-09

    Registered record
    Registry ID
    NCT01953367
    Conditions
    Cystic Fibrosis
    Interventions
    Vantobra (tobramycin); TOBI (tobramycin)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-09
    Completion
    2013-11
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionVantobra (tobramycin); TOBI (tobramycin)
    PhasePhase 1
    Registry statusCompleted

  • Antibiotic Prophylaxis for Transrectal Prostate Biopsy

    NCT01659866 · start 2012-08

    Registered record
    Registry ID
    NCT01659866
    Conditions
    Infection
    Interventions
    Ciprofloxacin; trimethoprim-sulfamethoxazole; cefuroxime; ceftriaxone; gentamicin; amikacin; aztreonam; imipenem; ceftriaxone; gentamicin; amikacin; aztreonam; imipenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-08
    Completion
    2016-08
    Enrolment
    563

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection
    InterventionCiprofloxacin; trimethoprim-sulfamethoxazole; cefuroxime; ceftriaxone +9 more
    PhasePhase 4
    Registry statusCompleted